Skill Checkup: An Elderly Man With Leg Pain and Weakness

Maria-Victoria Mateos, MD, PhD; Simon J. Harrison, MBBS, PhD


April 04, 2022

Pomalidomide plus low-dose dexamethasone is safe and effective as third-line therapy in patients with relapsed/refractory MM in whom lenalidomide-based or bortezomib treatment has failed. Immune profile analyses suggest that this regimen has persistent T-cell stimulatory activity directly after lenalidomide-based treatment. These results from Siegel et al support not only earlier sequencing of pomalidomide-based therapy after patients become refractory to lenalidomide but also the continued use and investigation of pomalidomide-based regimens that incorporate agents with complementary mechanisms of action in this patient population.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.